MedTrace Logo

An Observational Study on Long-Term Persistence of Resistant Mutations And Durability of Sustained Virological Response in Patients With Chronic Hepatitis C Treated With Direct Acting Antiviral (DAA)- Containing Regimens

NCT01168856 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 734

Last updated 2016-03-11

Study results available
· View outcomes & findings →

Summary

This observational long-term follow-up study will assess the persistence of direct acting antiviral (DAA) resistant mutations and the durability of sustained virological response in patients with chronic hepatitis C who have participated in a Roche DAA treatment protocol. Up to 5 scheduled monitoring visits for blood sampling during an observational period of up to 36 months.

Conditions

  • Hepatitis C, Chronic

Sponsors & Collaborators

Principal Investigators

  • Clinical Trials · Hoffmann-La Roche

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-09-30
Primary Completion
2015-04-30
Completion
2015-04-30

Countries

  • United States
  • Australia
  • Austria
  • Brazil
  • Canada
  • France
  • Germany
  • Italy
  • Mexico
  • New Zealand
  • Poland
  • Puerto Rico
  • Slovakia
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01168856 on ClinicalTrials.gov